Mobile

A Single-Arm, Phase 2 Trial of Pemetrexed, Cisplatin, and Bevacizumab as Induction, Followed by Pemetrexed and Bevacizumab as Maintenance, in First-Line Treatment of Nonsquamous Advanced NSCLC

Update Il y a 4 ans
Reference: EUCTR2008-006732-35

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

The primary objective of this Phase 2 study is to assess the efficacy of pemetrexed-cisplatin combined with bevacizumab as induction therapy and pemetrexed-bevacizumab as maintenance therapy in the first-line treatment of patients with Stage IIIB or IV nonsquamous NSCLC, as measured by PFS.

Inclusion criteria

  • Patients who have a histologically or cytologically documented diagnosis of nonsquamous stage IIIB or stage IV NSCLC that is not amenable to curative therapy

Links